114 related articles for article (PubMed ID: 21986528)
1. PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer.
Cho HJ; Baek KE; Nam IK; Park SM; Kim IK; Park SH; Im MJ; Ryu KJ; Yoo JM; Hong SC; Kim JW; Lee CW; Yoo J
Biochem Biophys Res Commun; 2011 Oct; 414(3):575-80. PubMed ID: 21986528
[TBL] [Abstract][Full Text] [Related]
2. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression.
Cho HJ; Baek KE; Park SM; Kim IK; Nam IK; Choi YL; Park SH; Im MJ; Choi J; Ryu J; Kim JW; Lee CW; Kang SS; Yoo J
Cancer Lett; 2011 Dec; 311(1):48-56. PubMed ID: 21752536
[TBL] [Abstract][Full Text] [Related]
3. Proteomics-based strategy to delineate the molecular mechanisms of RhoGDI2-induced metastasis and drug resistance in gastric cancer.
Cho HJ; Baek KE; Kim IK; Park SM; Choi YL; Nam IK; Park SH; Im MJ; Yoo JM; Ryu KJ; Oh YT; Hong SC; Kwon OH; Kim JW; Lee CW; Yoo J
J Proteome Res; 2012 Apr; 11(4):2355-64. PubMed ID: 22364609
[TBL] [Abstract][Full Text] [Related]
4. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer.
Cho HJ; Baek KE; Park SM; Kim IK; Choi YL; Cho HJ; Nam IK; Hwang EM; Park JY; Han JY; Kang SS; Kim DC; Lee WS; Lee MN; Oh GT; Kim JW; Lee CW; Yoo J
Clin Cancer Res; 2009 Apr; 15(8):2612-9. PubMed ID: 19351766
[TBL] [Abstract][Full Text] [Related]
5. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.
Cho HJ; Kim IK; Park SM; Baek KE; Nam IK; Park SH; Ryu KJ; Choi J; Ryu J; Hong SC; Jeong SH; Lee YJ; Ko GH; Kim J; Won Lee C; Soo Kang S; Yoo J
Int J Cancer; 2014 Oct; 135(7):1553-63. PubMed ID: 24585459
[TBL] [Abstract][Full Text] [Related]
6. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.
Wu Y; McRoberts K; Berr SS; Frierson HF; Conaway M; Theodorescu D
Oncogene; 2007 Feb; 26(5):765-73. PubMed ID: 16878152
[TBL] [Abstract][Full Text] [Related]
7. RhoGDI2 as a therapeutic target in cancer.
Cho HJ; Baek KE; Yoo J
Expert Opin Ther Targets; 2010 Jan; 14(1):67-75. PubMed ID: 20001211
[TBL] [Abstract][Full Text] [Related]
8. 14-3-3σ attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.
Kim IK; Park SM; Cho HJ; Baek KE; Nam IK; Park SH; Ryu KJ; Ryu J; Choi J; Hong SC; Kim JW; Lee CW; Kang SS; Yoo J
Oncotarget; 2013 Nov; 4(11):2045-56. PubMed ID: 24185104
[TBL] [Abstract][Full Text] [Related]
9. Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis.
Hu LD; Zou HF; Zhan SX; Cao KM
Oncol Rep; 2007 Jun; 17(6):1383-9. PubMed ID: 17487395
[TBL] [Abstract][Full Text] [Related]
10. FBXL5 attenuates RhoGDI2-induced cisplatin resistance in gastric cancer cells.
Wu WD; Wang M; Ding HH; Qiu ZJ
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2551-7. PubMed ID: 27383304
[TBL] [Abstract][Full Text] [Related]
11. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer.
Gildea JJ; Seraj MJ; Oxford G; Harding MA; Hampton GM; Moskaluk CA; Frierson HF; Conaway MR; Theodorescu D
Cancer Res; 2002 Nov; 62(22):6418-23. PubMed ID: 12438227
[TBL] [Abstract][Full Text] [Related]
12. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2.
Titus B; Frierson HF; Conaway M; Ching K; Guise T; Chirgwin J; Hampton G; Theodorescu D
Cancer Res; 2005 Aug; 65(16):7320-7. PubMed ID: 16103083
[TBL] [Abstract][Full Text] [Related]
13. Induction of ER stress protects gastric cancer cells against apoptosis induced by cisplatin and doxorubicin through activation of p38 MAPK.
Feng R; Zhai WL; Yang HY; Jin H; Zhang QX
Biochem Biophys Res Commun; 2011 Mar; 406(2):299-304. PubMed ID: 21320468
[TBL] [Abstract][Full Text] [Related]
14. Functional implications of caspase-mediated RhoGDI2 processing during apoptosis of HL60 and K562 leukemia cells.
Choi MR; Groot M; Drexler HC
Apoptosis; 2007 Nov; 12(11):2025-35. PubMed ID: 17726646
[TBL] [Abstract][Full Text] [Related]
15. RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation.
Harding MA; Theodorescu D
Urol Oncol; 2007; 25(5):401-6. PubMed ID: 17826660
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer.
Theodorescu D; Sapinoso LM; Conaway MR; Oxford G; Hampton GM; Frierson HF
Clin Cancer Res; 2004 Jun; 10(11):3800-6. PubMed ID: 15173088
[TBL] [Abstract][Full Text] [Related]
17. Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines.
Xu H; Choi SM; An CS; Min YD; Kim KC; Kim KJ; Choi CH
Biochem Biophys Res Commun; 2005 Mar; 328(2):618-22. PubMed ID: 15694393
[TBL] [Abstract][Full Text] [Related]
18. A role for phospholipase C-gamma-mediated signaling in tumor cell invasion.
Kassis J; Moellinger J; Lo H; Greenberg NM; Kim HG; Wells A
Clin Cancer Res; 1999 Aug; 5(8):2251-60. PubMed ID: 10473113
[TBL] [Abstract][Full Text] [Related]
19. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function.
Wu Y; Moissoglu K; Wang H; Wang X; Frierson HF; Schwartz MA; Theodorescu D
Proc Natl Acad Sci U S A; 2009 Apr; 106(14):5807-12. PubMed ID: 19321744
[TBL] [Abstract][Full Text] [Related]
20. Mutated D4-guanine diphosphate-dissociation inhibitor is found in human leukemic cells and promotes leukemic cell invasion.
Nakata Y; Kondoh K; Fukushima S; Hashiguchi A; Du W; Hayashi M; Fujimoto J; Hata J; Yamada T
Exp Hematol; 2008 Jan; 36(1):37-50. PubMed ID: 18037226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
